Eli Lilly And Co vs PulteGroup, Inc. — how do they compare? Eli Lilly And Co trades at $1,211.73 (market cap $1.08T), while PulteGroup, Inc. trades at $132.77 (market cap $25.22B). The key difference: Eli Lilly And Co is far larger — about 42.8× PulteGroup, Inc.'s market cap, and PulteGroup, Inc. pays the higher dividend (0.79%). Which is the better fit depends on your goals.
| LLY | PHM | |
|---|---|---|
Market Cap | $1.08T | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $142.56 |
52-Week Low | $639.43 | $110.11 |
Enterprise Value | $1.13T | $25.64B |
Dividend Yield | 0.57% | 0.79% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
PulteGroup (PHM) trades at $130.05, down 2.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025 and Q1 2026. Recent news highlights operational expansion into Northwest Florida and corporate recognition as a Great Place to Work, while financials indicate solid profitability with an 11.62% net margin and a P/E of 13.53.
Outlook remains cautiously optimistic with a consensus price target of $137.20, suggesting modest upside. Risks include margin pressure from housing market affordability challenges and volatile cash flows. Institutional sentiment leans neutral with 50% hold ratings, reflecting balanced Wall Street views amid industry headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →